Oregon Health and Science University
OHSU Knight Cancer Institute
Portland, OR
Filters
Save & Share
Clear Filters
Diagnosis
Risk Level
If known, please select your risk level (IPSS-R / IPSS-M).
MDS Centers of Excellence
Accepting patients
Orca-T
A Randomized Phase III Trial of Patients With Advanced Hematologic Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation With Either Orca-T, a T-cell-Depleted Graft With Additional Infusion of Conventional T Cells and Regulatory T Cells, or Standard-of-Care Allogeneic Graft
Learn more- Allogeneic Stem Cell Transplant
- T Cell (Allogeneic)
- Phase 3
- Has results
Accepting patients
Venetoclax and Azacitidine for Therapy-Related MDS
Phase II Study of Clinical Efficacy of Venetoclax in Combination With Azacitidine in Patients With Therapy Related Myelodysplastic Syndrome (t-MDS)
Learn more- BCL-2 Inhibitor
- Hypomethylating Agents (HMA)
- Phase 2
All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.
Help me find trialsAccepting patients
SAR443579
An Open-label, First-in-human, Dose-escalation/Expansion Study of SAR443579 Administered as Single Agent by Intravenous Infusion in Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL) or High Risk-myelodysplasia (HR-MDS)
Learn more- Trispecific NK Engager
- Phase 1/2
- Has results
Accepting patients
Orca-T
A Multicenter Phase Ib Trial of Patients With Advanced Hematologic Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation With Orca-T (Formerly TregGraft), a T-cell-Depleted Graft With Additional Infusion of Conventional T Cells and Regulatory T Cells
Learn more- T Cell (Allogeneic)
- Phase 1
- Has results
Accepting patients
OPTIMIZE
A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide as GvHD Prophylaxis in Adult Patients With Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Learn more- Allogeneic Stem Cell Transplant
- Phase 2
Accepting patients
SGR-2921
A First-In-Human, Phase 1, Dose Escalation Study of SGR-2921 as Monotherapy In Subjects With Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Learn more- CDC7 Inhibitor
- Phase 1
Accepting patients
ACCESS
ACCESS: A Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide for Patients with Hematologic Malignancies
Learn more- Allogeneic Stem Cell Transplant
- Pre-Transplant
- Phase 2
Accepting patients
ASTX030
A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)
Learn more- DNMT1 Inhibitor
- Phase 2/3
Accepting patients
NC525
A Phase 1, Open-Label, Safety, Tolerability, And Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms
Learn more- Monoclonal Antibody
- Phase 1
Accepting patients
SELECT MDS-1
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Tamibarotene Plus Azacitidine Versus Placebo Plus Azacitidine in Newly Diagnosed, Adult Patients Selected for RARA-positive Higher-risk Myelodysplastic Syndrome (SELECT MDS-1)
Learn more- Hypomethylating Agents (HMA)
- RAR-α / NR1B1
- Phase 3
Filters
Save & Share
Diagnosis
Risk Level
If known, please select your risk level (IPSS-R / IPSS-M).
MDS Centers of Excellence
Advanced Filters
Hide Trials
These are additional options that allow you to hide (or filter out) trial options that may not be right for you.
Trial Enrollment Status
Treatment Classifications
Filter results based on treatment classifications/type.
Trial Type
Phase
MDS Classification
Has your MDS been classified as primary (cause unknown) or secondary (treatment related)?